The Fox Chase Chemical Diversity Center is Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Development of Drugs that Target the M2 Proton Channel from Influenza Virus”
Doylestown, PA. February 2, 2015- FCCDC is pleased to announce that it has been awarded a Phase I SBIR grant entitled “Development of Drugs that Target the M2 Proton Channel from Influenza Virus” (R43AI104121-01A1).